ArticleMaterials today. Bio2025
Restoring macrophage iron homeostasis by natural carrier-free nanoplatform for the therapy of rheumatoid arthritis syndromes.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Metal-dependent regulated cell death: Molecular architecture and translational frontiers.iMeta · 2026Review
- Research progress on self-assembled supramolecular bioactive materials from herbal natural products and their applications in anti-infection field.Materials today. Bio · 2026Review
- Natural products in treating sepsis-associated lung and liver injuries by mediating ferroptosis, current progress, and future perspective.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Focal iron overload frequently induce macrophage polarization towards pro-inflammatory subtypes, leading to joint inflammation, cartilage damage and anemia in rheumatoid arthritis (RA) patients. Faced with the complex and lingering pathogenesis of RA, there is an urgent need to develop safe and effective strategies. The active ingredients from traditional herbal pair, namely roburic acid (RBA) and tetramethylpyrazine (TMP), have potential values in the anti-inflammatory and antiplatelet aggregation biological activities. However, their poor water solubility and low bioavailability limit their strong clinical application. To break this bottleneck, we developed a carrier-free nanomedicine (RTNs) through the self-assembly of RBA and TMP for RA syndromes treatment. RTNs formed through electrostatic interactions and hydrogen bonding exhibited strong inflammatory joint accumulation and long-term circulation in adjuvant-induced arthritis (AIA) rodents model. At the same time, RTNs outperformed the same doses of free RBA and TMP in the terms of good therapeutic effects in inhibiting joint inflammation, improving cartilage destruction, and alleviating RA secondary anemia. What's more, RTNs demonstrated good safety and biocompatibility. Finally, with the help of single-cell sequencing analysis and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.